SCHEMBL6824765

SCHEMBL6824765

Cc1ccc(-c2cc3cc(OC(F)(F)F)ccc3[nH]2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.56
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
KMT2A Q03164 4/20 0.51
MAPT P10636 4/20 0.51
MEN1 O00255 3/20 0.51
TRPA1 O75762 2/20 0.47
GAA P10253 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 4/20 0.46
LMNA P02545 2/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6118327 0.85 KDM4E (0.66) KDM4ENPC1RAB9AKMT2AMAPT
SCHEMBL15058692 0.82 KDM4E (0.74) KDM4ENPC1RAB9AKMT2AMAPT
SCHEMBL1459067 0.80 CYP19A1 (0.59) KDM4ENPC1RAB9AKMT2AMAPT
SCHEMBL2975733 0.79 AXL (0.64) KDM4EKMT2AMAPTMEN1TRPA1
SCHEMBL16382914 0.78 RAB9A (0.63) KDM4ENPC1RAB9AKMT2AMAPT
SCHEMBL29737280 0.78 RAB9A (0.65) KDM4ENPC1RAB9AKMT2AMAPT
SCHEMBL702063 0.78 RAB9A (0.65) KDM4ENPC1RAB9AKMT2AMAPT
SCHEMBL18770065 0.77 CYP19A1 (0.51) KDM4ENPC1RAB9AKMT2AMAPT
SCHEMBL22185223 0.77 KDM4E (0.55) KDM4EKMT2AMAPTTRPA1GAA
SCHEMBL11651810 0.76 KDM4E (0.67) KDM4ENPC1RAB9AKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R KDM4E 2605/4885NPC1 789/4885RAB9A 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.